Clonal Hematopoiesis of Immunological Significance — CHIS  

Lymphoma Clinical Trial

Official title: National Cohort of Patients With Dysimmune Manifestations With or Without Clonal Hematopoiesis

Status Not yet recruiting

Clinical Trial Summary

Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.

Clinical Trial Description

The clinical spectrum of dysimmune manifestations associated with blood diseases is wide. The pathophysiology of these manifestations is not well understood and their management is poorly codified. This observational cohort aims to list the different clinical pictures, the therapeutic management and the prognosis of patients according to the type of dysimmune manifestations and the type of hemopathy. We wish to have an inventory of the demographic, genetic, clinical and evolutionary data of patients with an inflammatory manifestation associated or not with a myeloid or lymphoid hemopathy. This will make it possible to establish quantitative data on the morbidity and mortality of these rare diseases and to propose therapeutic trials for the most serious patients. ;

Related Conditions & MeSH terms

• Autoimmune Diseases
• Autoinflammatory Diseases
• Clonal Hematopoiesis of Indeterminate Potential
• Hematologic Diseases
• Immune System Diseases
• Inflammation
• Leukemia
• Lymphoma
• Lymphoproliferative Disorders
• Monoclonal Gammopathy of Undetermined Significance
• Myelodysplastic Syndromes
• Myelodysplastic-Myeloproliferative Diseases
• Myeloproliferative Disorders
• Paraproteinemias
• Syndrome

• NCT number: NCT05969821
• Study type: Observational [Patient Registry]
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: Arsene MEKINIAN, MD PhD
• Phone: +33149282392
• Email: arsene.mekinian@aphp.fr
• Status: Not yet recruiting
• Start date: September 2023
• Completion date: September 2043